Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01555944
Other study ID # MyCard
Secondary ID
Status Completed
Phase N/A
First received March 14, 2012
Last updated April 22, 2016
Start date February 2012
Est. completion date April 2016

Study information

Verified date April 2016
Source Teva Pharma
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an open, multicentre, prospective observational (non-interventional) study, performed in Belgium.

Principal objectives:

1. To evaluate the prevalence of cardiovascular risk factors and cardiac function (as routinely evaluated) before treatment with anthracyclines of patients with metastatic breast cancer (MBC) aged > or = 65 years

2. To observe the management of cardiovascular risk during and after anthracycline treatment

3. To compare liposomal versus non-liposomal anthracycline therapy (ratio 1:1) on cardiac function, outcome and quality of life (EORTC QLQ-C30)

Secondary objectives:

1. To evaluate the efficacy of anthracyclines on progression free survival and tumor response as routinely measured (e.g. recist criteria, tumor markers and other exams)

2. To evaluate cardiovascular event type: ECG changes, arrhythmia, decrease of ejection fraction, heart failure and rate according to allocated treatment.

3. To find out how quality of life, e.g. such as described according to EORTC QLQ-C30 criteria or Karnofsky index is achieved in the various patient subgroups

4. To correlate the therapeutic choice and posology of anthracyclines for MBC with Cardiovascular risk at baseline

5. To calculate the cardiovascular risk according to SCORE


Description:

The physician will be requested:

- To include 15 consecutive patients aged > or = 65 years who will be treated with anthracyclines in first and second line MBC. The physician will be encouraged to enrol 2 arms of 8 patients (one treated with liposomal and one with non-liposomal anthracyclines) for observation and comparison. Each arm will be closed as soon as 150 patients are included at a national level.

- To report their cardiovascular risk factors

- To provide the results of routinely performed cardiac evaluation before treatment

- To monitor routinely cardiovascular parameters during treatment and report them afterwards

- To monitor efficacy and tolerance of treatments, as normal practice prescribes, reported and related to the variables described in objectives

- To ensure that quality of life will be assessed with the EORTC QLQ-C30 questionnaire

- To monitor and report progression free survival and cardiac events

- To record and transmit spontaneously reported adverse events. These will be handled according to legal requirements

Follow-up will cover a period of 15 months following inclusion.

The study will have 3 visits and 2 contacts:

- One visit at entry

- One visit after 3 cycles of anthracycline containing therapy

- One visit at the end of treatment

- Contact at 9 months after inclusion

- Contact at 15 months after inclusion

It is planned to include data from 15 consecutive female patients per specialized center in Belgium.

The total number of patients aimed is 300.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date April 2016
Est. primary completion date April 2016
Accepts healthy volunteers No
Gender Female
Age group 65 Years and older
Eligibility Inclusion Criteria:

- women aged 65 years old or more

- with confirmed metastatic breast cancer (MBC)

- who will be treated with anthracyclines in first or second line

- who have a Karnofsky score at baseline of 50

- who agree and are able to fill in the EORTC QLQ-C30 questionnaire

- who gave their informed consent

Exclusion Criteria:

- women having contra-Indications for anthracyclines

- women aged < 65 years old

- with no metastatic breast cancer

- who will not be eligible for an anthracycline treatment in first or second line MBC

- who have a Karnofsky less than 50

- who disagree or are unable to fill in the EORTC QLQ-C30 questionnaire

- women refusing or not having signed their informed consent

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Belgium ZNA Middelheim Antwerp
Belgium Cliniques du Sud Lux - St Joseph Arlon
Belgium Imelda Bonheiden
Belgium Clinique Saint-Luc Bouge
Belgium AZ KLINA Brasschaat
Belgium AZ St Jan Brugge
Belgium UZ Brussel Brussel
Belgium CHIREC - Centre Hospitalier Interrégional Edith Cavell Brussels
Belgium CHU Brugmann Brussels
Belgium Erasme Brussels
Belgium CSF Chimay
Belgium AZ St-Maarten Duffel
Belgium UZA Edegem
Belgium AZ St-Dimpna Geel
Belgium AZ St-Lucas Ghent
Belgium ZNA Jan Palfijn Merksem
Belgium CHR Namur
Belgium CMSE Namur
Belgium AZ Damiaan Oostende
Belgium Clinique St Pierre Ottignies
Belgium AZ Nikolaas St-Niklaas
Belgium Centre Hospitalier de Wallonie picarde - site IMC Tournai
Belgium CHPLT Verviers
Belgium CHU Mont-Godinne Yvoir

Sponsors (1)

Lead Sponsor Collaborator
Teva Pharma

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary cardiovascular risk factors 15 months
See also
  Status Clinical Trial Phase
Withdrawn NCT04872608 - A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Phase 1
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Completed NCT02506556 - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer Phase 2
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Recruiting NCT03368729 - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Completed NCT04103853 - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer Phase 1
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Active, not recruiting NCT03147287 - Palbociclib After CDK and Endocrine Therapy (PACE) Phase 2
Not yet recruiting NCT06062498 - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT04095390 - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Phase 2
Active, not recruiting NCT04432454 - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Phase 2
Recruiting NCT03323346 - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Phase 2
Recruiting NCT05744375 - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab Phase 2
Completed NCT02924883 - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy Phase 2
Completed NCT01942135 - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Phase 3
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT01401959 - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Phase 2
Terminated NCT04720664 - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer Phase 2